Additional PPOs to Cover Signal Genetics Multiple Myeloma Test | GenomeWeb

NEW YORK (GenomeWeb) – Signal Genetics today announced agreements with three preferred provider organizations to cover the firm's multiple myeloma prognostic molecular diagnostic test.

The deals are with Stratose, USA Managed Care Organization, and Evolutions Health Systems, and provide covered access to Signal Genetics' MyPRS test to more than 21 million patients in the US. In total, more than 93 million patients in the US are covered for the test by payors, the Carlsbad, California-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.